Research Perspective Volume 2, Issue 3 pp 160—165

Figure 1. The p53/p19ARF status of various MEF lines derived from normal strain 129 mice. MEF cell lines genotyped as either wild-type (WT) p53 or mutant (MT) p53 (both heterozygous and homozygous) were compared against those carrying the p19/ARF deletion in their response to doxorubicin (8h, 1μM) treatment. Cells were methanol fixed and processed by indirect immunofluorescence confocal microscopy with either the anti-p53 CM5 (Novacastra) or anti-p19/ARF ab80 (AbCam) antibody. Scale bar represents 50μm. All samples were processed at the same intensity and magnification.